Posted inClinical Updates news Oncology Specialties
Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival
The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.